Vikneswaran Mathiyazakan

Abstract The cytochrome bcc:aa3 oxidase is the target of telacebec, a clinically advanced drug developed for Mycobacterium tuberculosis. However, telacebec is inactive against Mycobacterium abscessus, an opportunistic pathogen increasingly linked to chronic pulmonary infections and notoriously known for intrinsic resistance to numerous antibiotics. Here, we report the 2.6 Å cryo-electron microscopy structure of the M.

Chemical Synthesis Additional details of synthetic methodology of lead compounds ETX2234-2 and ETX1975-3 and their respective parent compound are summarized in Supporting Information (M1, M2, M3, M4, and M5). All starting materials, reagents, and solvents were obtained from commercial vendors and used as received. All reactions were carried out under a nitrogen atmosphere in dry solvents, unless otherwise mentioned.

Introduction Click to copy section linkSection link copied! Tuberculosis (TB) continues to pose a significant global public health threat, as the leading cause of deaths attributable to a single infectious agent, Mycobacterium tuberculosis. According to the World Health Organization (WHO), 10.6 million people developed active tuberculosis and 1.25 million died from the disease in 2023. (1) Although there was a decrease from previous years, the numbers remain substantial.